» Articles » PMID: 11082448

Antidepressant-like Behavioral Effects Mediated by 5-Hydroxytryptamine(2C) Receptors

Overview
Specialty Pharmacology
Date 2000 Nov 18
PMID 11082448
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

The role of the 5-HT(2C) receptor in mediating active behaviors in the modified rat forced swim test was examined. Three novel selective 5-HT(2C) receptor agonists, WAY 161503 (0.1-3.0 mg/kg), RO 60-0175 (2-20 mg/kg), and RO 60-0332 (20 mg/kg), all decreased immobility and increased swimming, a pattern of behavior similar to that which occurs with the selective serotonin reuptake inhibitor fluoxetine (5-20 mg/kg). However, the prototypical but nonselective 5-HT(2C) receptor agonist m-chlorophenylpiperazine (1-10 mg/kg) increased immobility scores in the forced swim test. The selective 5-HT(2C) receptor antagonist SB 206533 was inactive when given alone (1-20 mg/kg). However, SB 206533 (20 mg/kg) blocked the antidepressant-like effects of both WAY 161503 (1 mg/kg) and fluoxetine (20 mg/kg). The atypical antidepressant (noradrenergic alpha(2) and 5-HT(2C) receptor antagonist) mianserin reduced immobility and increased climbing at 30 mg/kg. At a behaviorally subactive dose (10 mg/kg), mianserin abolished the effects of WAY 161503 (1 mg/kg) on both swimming and immobility scores. Mianserin blocked the effects of fluoxetine (20 mg/kg) on swimming only; mianserin plus fluoxetine reduced immobility and induced a switch to climbing behavior, suggesting activation of noradrenergic transmission. These data exemplify the benefits of using the modified rat forced swim test, which was sensitive to serotonergic compounds and distinguished behavioral changes associated with serotonergic and noradrenergic effects. Taken together, the results strongly implicate a role for 5-HT(2C) receptors in the behavioral effects of antidepressant drugs.

Citing Articles

Neuroplasticity and Mechanisms of Action of Acute and Chronic Treatment with Antidepressants in Preclinical Studies.

Rosas-Sanchez G, German-Ponciano L, Guillen-Ruiz G, Cueto-Escobedo J, Limon-Vazquez A, Rodriguez-Landa J Biomedicines. 2025; 12(12.

PMID: 39767650 PMC: 11727250. DOI: 10.3390/biomedicines12122744.


Cognitive dysfunction in early experimental metabolic dysfunction-associated steatotic liver disease is associated with systemic inflammation and neuroinflammation.

Kjaergaard K, Mikkelsen A, Landau A, Eriksen P, Hamilton-Dutoit S, Magnusson N JHEP Rep. 2024; 6(3):100992.

PMID: 38415019 PMC: 10897893. DOI: 10.1016/j.jhepr.2023.100992.


G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders.

Wong T, Li G, Li S, Gao W, Chen G, Gan S Signal Transduct Target Ther. 2023; 8(1):177.

PMID: 37137892 PMC: 10154768. DOI: 10.1038/s41392-023-01427-2.


Evaluation of the 5-HT receptor drugs RO 60-0175, WAY 161503 and mirtazepine in a preclinical model of comorbidity of depression and cocaine addiction.

Jastrzebska J, Frankowska M, Smaga I, Hubalewska-Mazgaj M, Suder A, Pieniazek R Pharmacol Rep. 2022; 75(1):99-118.

PMID: 36374478 PMC: 9889480. DOI: 10.1007/s43440-022-00428-2.


Encore: Behavioural animal models of stress, depression and mood disorders.

Petkovic A, Chaudhury D Front Behav Neurosci. 2022; 16:931964.

PMID: 36004305 PMC: 9395206. DOI: 10.3389/fnbeh.2022.931964.